Cost Considerations in Determining the Affordability of Adjuvant Trastuzumab in Breast Cancer

South African Medical Journal - South Africa
doi 10.7196/samj.2016.v106i10.11141
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

South African Medical Association NPC

Related search

Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines

BMC Health Services Research
Health Policy
2019English

Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

New England Journal of Medicine
Medicine
2005English

Cost-Utility Analysis of Adjuvant Therapies for Breast Cancer in Iran

International Journal of Technology Assessment in Health Care
Health Policy
2012English

PCN114 Cost Effectiveness of Adjuvant Cyclophosphamide in the Treatment of Breast Cancer in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Adjuvant Trastuzumab for Breast Cancer: An Increasingly Common Ethical and Economic Conundrum

BMJ
2005English

Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Adjuvant Bisphosphonates in Breast Cancer Treatment

Breast Care
SurgeryOncology
2014English

Resource Utilization and Cost Saving Analysis of Subcutaneous Versus Intravenous Trastuzumab in Early Breast Cancer Patients

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy